For the quarter ending 2025-09-30, PALI made $2,981K in revenue. -$2,868K in net income. Net profit margin of -96.21%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and development | 1,394 | 1,675 | 2,309 | 2,137 |
| General and administrative | 1,528 | 1,168 | 1,447 | 1,456 |
| Total operating expenses | 2,922 | 2,843 | 3,755 | 3,593 |
| Loss from operations | -2,922 | -2,843 | -3,755 | -3,593 |
| Interest expense | 5 | 2 | 2 | 6 |
| Other income, net | 59 | 61 | 107 | 112 |
| Total other income, net | 54 | 59 | 105 | 106 |
| Net loss | -2,868 | -2,784 | -3,650 | -3,487 |
| Basic net loss per common share | -0.38 | -0.58 | -2.623 | -2.32 |
| Diluted net loss per common share | -0.38 | -0.58 | -2.623 | -2.32 |
| Weighted average shares used in calculating basic loss per common share | 7,473,898 | 4,797,196 | -27,979.333 | 1,500,409 |
| Weighted average shares used in calculating diluted loss per common share | 7,473,898 | 4,797,196 | -27,979.333 | 1,500,409 |
PALISADE BIO, INC. (PALI)
PALISADE BIO, INC. (PALI)